XASX
SOM
Market cap44mUSD
Oct 09, Last price
0.28AUD
1D
-5.17%
1Q
-43.88%
Jan 2017
-92.83%
IPO
-93.52%
Name
Somnomed Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. It provides SomnoDent Avant, as well as SomnoDent Classic, SomnoDent Flex, and SomnoDent Fusion are offered for the treatment of obstructive sleep apnea. The company also offers SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.
Key people
Peter Neustadt
Non-Executive Chairman of the Board · since 2016
Kien T. Nguyen
President - SomnoMed Inc. · since 2012
Neil Robert Verdal-Austin
Chief Executive, Chief Financial Officer · since 2018
Herve Fievet
Chief Financial Officer · since 2019
James R. Evanger
President, Chief Executive Officer of Sleep Centres America, Inc · since 2016
Matthew Conlon
Executive Vice President of Sales and Marketing · since 2019
Christopher Bedford
Vice President - Global Production and Product Development · since 2014
Company Secretary · since 2004
Hamish Corlett
Director · since 2018
Non-Executive Independent Director · since 2011
Robert Scherini
Non-Executive Independent Director · since 2011
Legal address
20 CLARKE STREET
CROWS NEST, NSW 2065
AU
CROWS NEST, NSW 2065
AU
Headquarters
LEVEL 3, 20 CLARKE STREET
CROWS NEST, NSW 2065
AU
CROWS NEST, NSW 2065
AU
Previous name
INDO PACIFIC SECURITIES LTD
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||